Ovid Therapeutics (OVID) shares jumped over 40% premarket as the biopharmaceutical company reported favorable safety and tolerability results for the 7 mg dose of its OV329 epilepsy drug, while ...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in ...

Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase ...

Ovid Therapeutics Inc. (NASDAQ:OVID) said Wednesday it has raised $60 million through a private placement to support the ...

Ovid Therapeutics (NASDAQ:OVID) outlined new pipeline and financing updates alongside its fourth-quarter and full-year 2025 results, highlighting regulatory clearance in Australia for its KCC2 direct ...

Detailed price information for Ovid Therapeutics Inc (OVID-Q) from The Globe and Mail including charting and trades.

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile ...

At first, the moment seemed purely sweet to mom Natalie Sharp—a big sister carefully taking responsibility.

Researchers from The University of Osaka find that potassium KCNQ2/3 channels, which are important for suppressing brain cell ...

Shares of Ovid Therapeutics climbed after the company swung to a profit in the fourth quarter and said it would expand one of its therapies to explore additional use cases. The stock rose 22%, to ...

Ovid Therapeutics Inc. OVID shares are up during Wednesday’s session following the company’s announcement of new data regarding OV329 and the initiation of a Phase 1 trial for OV4071. Epilepsy Data ...

Detailed price information for Eton Pharmaceutcials Inc (ETON-Q) from The Globe and Mail including charting and trades.